Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts

Presented at ISPOR 2024

I Petit1, L Eliasson2, B Romero3, C Patel2, A Di Rosa3, J Quinn1

1 Debiopharm SA, Switzerland
2Sprout Health Solutions Limited, UK
3Sprout Health Solutions Limited, US